CARsgen Claims First Clinical Win For CLDN 18.2 CAR-T In G/GEJ Adenocarcinoma
CARsgen's anti-Claudin 18.2 CAR-T therapy satricabtagene autoleucel has met its endpoint in a pivotal Phase II trial in later-stage gastric/gastroesophageal junction adenocarcinoma, paving the way for a China NDA filing.
![3D illustration of T cells attacking a cancer cell (CAR-T cell therapy) - Illustration](https://insights.citeline.com/resizer/v2/BCJ43VT7IJJY5A2PVRK7NL2QQI.jpg?smart=true&auth=19b0a76e482727791e4daf43aef38b63091c02ea26ae7dc1e568c6852465d08c&width=700&height=394)